Factors Associated with Survival and Discontinuation of Anti-Malarial Agents in Systemic Lupus Erythematosus: Results from a Tertiary Swedish Referral Centre
<b>Background:</b> Antimalarial agents (AMAs) are cornerstone drugs in the treatment of systemic lupus erythematosus (SLE), and their use has established benefits, such as improved prognosis and decelerated accrual of organ damage. The aim of this study was to investigate the frequency o...
Main Authors: | Tomas Walhelm, Lina Wirestam, Yvonne Enman, Ioannis Parodis, Christopher Sjöwall |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-03-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/13/5/1485 |
Similar Items
-
Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies
by: Xian-Bao Li, et al.
Published: (2021-01-01) -
Between a rock and a hard place: management of systemic lupus erythematosus and porphyria cutanea tarda
by: Timothy Nyckowski, et al.
Published: (2022-07-01) -
A case of lupus erythematosus panniculitis misdiagnosed as vasculitis
by: Yuqi TANG, et al.
Published: (2023-04-01) -
Lupus erythematosus tumidus – rzadka odmiana przewlekłej skórnej postaci tocznia rumieniowatego
by: Małgorzata Sokołowska-Wojdyło, et al.
Published: (2011-08-01) -
Evaluation of Hydroxychloroquine Blood Concentrations and Effects in Childhood-Onset Systemic Lupus Erythematosus
by: Noël Zahr, et al.
Published: (2021-03-01)